Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Zhifei DTaP (Component) Vaccine in Infants
NCT06344065Phase 3Recruiting
- Sponsor
- Zhifei Green Bamboo
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis vaccine in diphtheria, Tetanus and pertussis (3 arms), sponsored by Zhifei Green Bamboo. Primary endpoints: Immunogenicity results of experimental group and active control group (DTaP) and Immunogenicity results of experimental group and active control group (DTaP-IPV//PRP-T). Started Dec 2023; status: recruiting.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT06344065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344065.